logo
Plus   Neg
Share
Email

Stars Group To Acquire Remaining 20% Of BetEasy - Quick Facts

The Stars Group Inc. (TSG, TSGI.TO) announced Monday that it has agreed with the minority shareholders of BetEasy, its Australian-based sports betting business, to acquire the remaining 20 percent interest in the company for A$151 million.

As part of this agreement, The Stars Group also agreed to pay A$100 million to settle the previously disclosed performance payment under the agreements for its 2018 acquisition of the initial 80 percent interest.

The Stars Group currently expects to complete the minority acquisition within 90 days following the earlier of either the issuance of The Stars Group's audited financial statements for the year-ended December 31, 2020 or the completion of the previously announced board-recommended all share combination of The Stars Group with Flutter Entertainment Plc.

The purchase price will be settled in cash unless it follows the completion of the combination, in which case Flutter may elect to settle in cash, Flutter ordinary shares or a combination of the same.

In addition to the acquisition of the remaining interest, The Stars Group will settle the performance, or earn-out, payment to the minority shareholders for A$100 million. The performance payment, which could have reached A$232 million, was subject to certain performance conditions primarily related to BetEasy's EBITDA.

Also as part of the agreement, The Stars Group will repay A$56.9 million of outstanding BetEasy minority shareholder loans.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
New York Attorney General Letitia James has fled a lawsuit against Vyera Pharmaceuticals and two of its former CEOs, including imprisoned 'Pharma Bro' Martin Shkreli, for illegally monopolizing a life-saving drug Daraprim. The lawsuit seeks a lifetime ban on Shkreli and his business partner Kevin Mulleady working in the pharmaceutical industry. Graco Inc. (GGG) shares were climbing more than 7 percent in morning trade. Monday after market close, the company had reported a surge in the fourth-quarter earnings to $84.8 million from $73.7 million in the prior year. Earnings per share surpassed analysts' estimates. Sales were up 1 percent to $412.3... Strategy of getting multiple indication approvals for the same drug seems to be paying off for AstraZeneca PLC (AZN), in terms of higher likelihood of approval and improved sales. Besides, the company is realizing value from non-core, mature brands to invest in new drugs, which also seems to be working in its favor.
RELATED NEWS
Follow RTT
>